Improvement of Organ Function by Apigenin in Elderly Patients With Sepsis - Trial NCT05999682
Access comprehensive clinical trial information for NCT05999682 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Zhujiang Hospital and is currently Not yet recruiting. The study focuses on Sepsis,Septic Shock. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Zhujiang Hospital
Timeline & Enrollment
Phase 1/2
Aug 01, 2023
Dec 01, 2023
Primary Outcome
96-hour Sequential Organ Failure Assessment (SOFA) score
Summary
In this single-center, randomized, single-blind, placebo-controlled pilot clinical trial. The
 effect of apigenin on the improvement of organ function will be investigated in elderly
 patients with sepsis. Researchers will screen patients admitted to the Department of Critical
 Care Medicine at Zhujiang Hospital to identify patients with sepsis based on including and
 excluding criteria and obtain informed consent and randomize them into groups. The treatment
 group will be given apigenin tablets 50mg ground with 5ml of sterilized water for
 intra-gastric tube injection; the control group will be given an equal volume of sterilized
 water for intra-gastric tube injection. The changes in SOFA score and other clinically
 meaningful outcomes in 4 days will be collected.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05999682
Non-Device Trial